Insulin-like growth factor-I concentration and risk of prostate cancer: Results from the European prospective investigation into cancer and nutrition

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 9, 2012, Pages 1531-1541

  Price, Alison J ^a   Allen, Naomi E ^a   Appleby, Paul N ^a   Crowe, Francesca L ^a   Travis, Ruth C ^a   Tipper, Sarah J ^a   Overvad, Kim ^d   Grønbæk, Henning ^e   Tjønneland, Anne ^f   Johnsen, Nina Føns ^f   Rinaldi, Sabina ^g   Kaaks, Rudolf ^h   Lukanova, Annie ^h   Boeing, Heiner ⁱ   Aleksandrova, Krasimira ⁱ   Trichopoulou, Antonia ^j,k   Trichopoulos, Dimitrios ^l,m   Andarakis, George ^k   Palli, Domenico ^o   Krogh, Vittorio ^p   Tumino, Rosario ^q   Sacerdote, Carlotta ^r   Bueno de Mesquita, H Bas ^s,t   Argüelles, Marcial V ^u   Sánchez, Maria José ^v,z   Chirlaque, Maria Dolores ^w,z   Barricarte, Aurelio ^x,z   Larrañaga, Nerea ^y,z   González, Carlos A ^aa   Stattin, Pär ^n,ab   Johansson, Mattias ^ab   Khaw, Kay Tee ^b   Wareham, Nick ^b   Gunter, Marc ^c   Riboli, Elio ^c   Key, Timothy ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d AARHUS UNIVERSITY   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁱ GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^j UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^k HELLENIC HEALTH FOUNDATION   (Greece)

^l BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^m HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^p NATIONAL CANCER INSTITUTE   (Italy)

^q Civile MP Arezzo Hospital   (Italy)

^r Human Genetics Foundation   (Italy)

^s NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^t UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^u Health and Health Care Services Council   (Spain)

^v ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^w Murcia Regional Health Authority   (Spain)

^x INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^y Public Health Department of Gipuzkoa   (Spain)

^z CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^aa CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^ab UMEÅ UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE DURATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUTRITION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

AGED; CASE-CONTROL STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK;

EID: 84866183841     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0481-T     Document Type: Article

References (23)

1. Grimberg A. Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2003;2:630-5.
2. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008;149:461-71.
3. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, et al. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the european prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2007;16:1121-7.
4. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European prospective investigation into cancer and nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
5. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol 1993;22:1189-92.
6. Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptornatic incidence and duration of prostate cancer. Am J Epidemiol 1998;148:775-85.
7. Rowlands MA, Holly JM, Gunnell D, Donovan J, Lane JA, Hamdy F, et al. Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res 2012;72:503-15.
8. Nimptsch K, Platz EA, Pollak MN, Kenfield SA, Stampfer MJ, Willett WC, et al. Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the health professionals follow-up study 1993-2004. Int J Cancer 2011;128:660-7.
9. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PDH, Sanders MM, et al. Prostate cancer and the will rogers phenomenon. J Natl Cancer Inst 2005;97:1248-53.
10. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Bastacky S, López Beltrán A, et al. The 2005 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228-42.
11. Schmidt C. Gleason scoring system faces change and debate. J Natl Cancer Inst 2009;101:622-9.
12. Platz EA, Pollak MN, Rimm EB, Majeed N, Tao Y, Willett WC, et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 1999;8:1107-10.
13. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106.
14. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005;16:255-62.
15. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592-600.
16. Gill JK, Wilkens LR, Pollak MN, Stanczyk FZ, Kolonel LN. Androgens, growth factors, and risk of prostate cancer: the multiethnic cohort. Prostate 2010;70:906-15.
17. Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak MD, et al. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study. Cancer Epidemiol Biomarkers Prev 2008;17:252-4.
18. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
19. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-89.
20. Allen NE, Appleby PN, Davey GK, Kaaks R, Rinaldi S, Key TJ. The associations of diet with serum insulin-like growth factor I and its main binding proteins in 292 women meat-eaters, vegetarians, and vegans. Cancer Epidemiol Biomarkers Prev 2002;11:1441-8.
21. Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002;11:852-61.
22. Crowe FL, Key TJ, Allen NE, Appleby PN, Roddam A, Overvad K, et al. The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the european prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2009;18:1333-40.
23. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996;28:619-37.